COX7RP contributes to endometrial and breast cancer growth.
Diagnosis of endometrial carcinoma made easier by analysis of mutations in cervix or endometrial tissue.
Many clinical trials in breast and endometrial cancers are underway and recruiting patients.
The combination was simultaneously approved in Australia and Canada and was the first such action under a new international collaboration.
Researchers identified a highly recurrent, disease-specific PP2A PPP2R1A mutation as a driver of endometrial carcinoma and as a target for new drugs.
Researchers examined the results of ribociclib and letrozole as a treatment for patients with estrogen receptor-positive ovarian cancer and endometrial cancer.
A new study reinforces the need for universal mismatch repair protein immunohistochemistry screening of tumors from endometrial cancer patients, as well as germline genetic testing in accordance with guidelines.
Dr. Makker summarizes the standard of care for the treatment of advanced endometrial cancer, with a look forward to the multitude of clinical trials evaluating novel therapy combinations that are currently enrolling patients or underway.
Cancer Network spoke with Yoland Catherine Antill, MD, of Cabrini Health, about the phase II PHAEDRA trial, which tested the activity of durvalumab in advanced endometrial cancer according to mismatch repair status.
Researchers studied the use of minimally invasive robotic surgery for hysterectomy and its risk for complications in the treatment of endometrial cancer in Denmark.